Skip to main content

Table 2 Incidence of hypermetabolic lymphadenopathy categories

From: Hypermetabolic lymphadenopathy following administration of BNT162b2 mRNA Covid-19 vaccine: incidence assessed by [18F]FDG PET-CT and relevance to study interpretation

All-Vac group
(n = 728)
Vac-1 group (n = 346) Vac-2 group (n = 346) Control group (n = 223) Pv
No HLN 396 (54..4%) 220 (63.6%) 176 (46.1%) 206 (92.4%) <0.01 a,b,c
HLN 332 (45.6%) 126 (36.4%) 206 (53.9%) 17 (7.6%)
 MHL 17 (2.3%) 10 (2.9%) 7 (1.8%) 17 (7.6%) <0.01 b,c
 EqHL 49 (6.7%) 25 (7.2%) 24 (6.3%)   0.61
 VAHL 266 (36.5%) 91 (26.3%) 175 (45.8%)   <0.01
  1. Categorical variables are reported as frequency and percentage
  2. aa significant difference was found between Vac-1 and Vac-2 groups
  3. ba significant difference was found between Vac-1 and control groups
  4. ca significant difference was found between Vac-2 and control groups